Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- European journal of cancer (Oxford, England : 1990)
- Publicado em
- 19 jun 2023
- Citações
- 15
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials
Alessandra Raimondi, Federico Nichetti, Arndt Stahler, Harpreet S Wasan, Enrique Aranda, Giovanni Randon, Annika Kurreck, Angela M Meade, Eduardo Díaz-Rubio, Monica Niger et al.
Descritores MeSH
- Rectal Neoplasms
- Colorectal Neoplasms
- Colonic Neoplasms
- Fluorouracil
- Humans
- Cetuximab
- Induction Chemotherapy
- Antineoplastic Combined Chemotherapy Protocols
- Leucovorin
Veja também
Estudos relacionados
- Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis
- A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials
- Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment
- Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study
- NALIRIFOX versus FOLFIRINOX: meta-análise individual de eficácia e segurança no tratamento de primeira linha de adenocarcinoma ductal pancreático irressecável ou metastático